Language:
Password reminder
No account yet? Register Free
About Us Advertising Info Contact Us Client Login
hospimedica.com
Features Subscription Partner Sites Journal Info
SIEMENS HEALTHCARE

Experimental Osteoporosis Drug Proves Safe at Therapeutic Dosage

By HospiMedica International staff writers
Posted on 26 Jan 2010


Researchers have established the therapeutic window and optimal safe dosage of parathyroid hormone-related protein (PTHrP), an experimental drug being tested for treatment of osteoporosis.

Investigators at the University of Pittsburgh School of Medicine (PA, USA) conducted a single-blinded, two-part, dose-escalating clinical trial that involved 41 healthy postmenopausal women between the ages of 45 and 75. Each subject received either PTHrP or a placebo in a dose-escalating regimen for a period of three weeks. During this period, safety measures (hypercalcemia, nausea, vomiting, hemodynamics, flushing, etc.) and bone turnover markers were measured.

Results of the study were published in the January 8, 2010, online edition of the Journal of Clinical Endocrinology and Metabolism. They revealed that daily doses of 500 and 625 micrograms could be tolerated without serious adverse events. Subjects receiving 750 micrograms per day developed mild hypercalcemia. Bone turnover markers suggested that even at the highest doses, daily treatment with PTHrP did not activate bone resorption (break down). When hypercalcemia occurred, it may have resulted not from bone resorption but from activation of intestinal calcium absorption by 1,25 dihydroxyvitamin D.

"When we studied PTHrP several years ago in small numbers of postmenopausal women with osteoporosis, we found that bone density increased by nearly 5% after only three months of treatment," said senior author Dr. Andrew F. Stewart, professor of endocrinology and metabolism at the University of Pittsburgh School of Medicine. "And even at the highest doses, the side effects were negligible."

A follow-up study will compare results of treatment with PTHrP to those obtained with teriparitide, a drug that already is FDA-approved for osteoporosis treatment. The study will involve 105 participants.

"We are very eager to find out how this new drug compares to a therapy that is currently available," said first author Dr. Mara Horwitz, assistant professor of medicine at the University of Pittsburgh School of Medicine. "Our previous studies suggest that it may increase bone density more dramatically with fewer side effects, but this is the first head-to-head comparison."

Related Links:

University of Pittsburgh School of Medicine





Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get complete access to news and events that shape the world of Hospital Medicine.
Free digital version edition of HospiMedica International sent by email on regular basis
Free print version of HospiMedica International magazine
(available only outside USA and Canada).
Free and unlimited access to back issues of HospiMedica International in digital format
Free HospiMedica International Newsletter sent every 2 weeks containing the latest news
Free breaking news sent via email
Free access to Events Calendar
Free access to LinkXpress new product services
REGISTRATION IS FREE AND EASY!


Click here to Register

Sign in: Registered website members
Username: Password:
Forgot username/password? Click here!
Sign in: Registered magazine subscribers
Subcode: Last Name:
What is SUBCODE?




Handheld Visualization Tool
Handheld Visualization Tool
Mobile X-Ray System
Mobile X-Ray System
Monopolar Scissors
Monopolar Scissors

More Products

Latest Women's Health News

LinkXpress
Click for LinkXpress
Reader Inquiry Service
Enter code to receive information:
Where I can find code?
Featured Videos
Siemens Healthcare:


siemens.com/pink
More Videos
Featured Whitepaper
ZOLL Int'lHolding:
High-Current vs. High-Energy Biphasic

Download Whitepaper
Events
KIMES 2012 - 28th Korea International Medical & Hospital Equipment Show
16 Feb 2012
19 Feb 2012


Medical Fair India 2012.
02 Mar 2012
04 Mar 2012


ChinaMed 2012.
23 Mar 2012
25 Mar 2012


More events
Latest Issue

View Digital Edition
Subscribe / Renew
  hospimedica.com Copyright © 2000-2012 Globetech Media. All rights reserved.
Privacy Policy